Medine Idrizoglu Gulcebi

Medine Idrizoglu Gulcebi

Auto-generated profile, based on publicly available information

Medine Idrizoglu Gulcebi

Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey; Epilepsy Research and Implementation Centre (EPAM), Marmara University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Epilepsy Research
Verified
Journal Article
Closed access
MGMedine Idrizoglu Gulcebi
Medine Idrizoglu Gulcebi
AOAydan Ozkaynakcı
Aydan Ozkaynakcı
MGMehmet Zafer Goren
Mehmet Zafer Goren
RARezzan Gulhan Aker
Rezzan Gulhan Aker
COCigdem Ozkara
Cigdem Ozkara
FOFiliz Yılmaz Onat
Filiz Yılmaz Onat

10 February 2021 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MGMedine I. Gulcebi
Medine I. Gulcebi
EBEmanuele Bartolini
Emanuele Bartolini
OLOmay Lee
Omay Lee
CLChristos Panagiotis Lisgaras
Christos Panagiotis Lisgaras
FOFiliz Onat
Filiz Onat
SSSanjay M. Sisodiya
Sanjay M. Sisodiya

1 February 2012 in Brain Research Bulletin
Verified
Journal Article
Closed access
MGMedine Idrizoglu Gulcebi
Medine Idrizoglu Gulcebi
DKDr. SEMA KETENCİ
Dr. SEMA KETENCİ
RLRudiger Linke
Rudiger Linke
HHHusniye Hacıoğlu
Husniye Hacıoğlu
HYHasan Yanalı
Hasan Yanalı
SÇSafiye Çavdar
Safiye Çavdar

10 January 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
RGRezzan Gülhan
Rezzan Gülhan
EEEmel Eryüksel
Emel Eryüksel
MOMedine Gülçebi İdRiz Oğlu
Medine Gülçebi İdRiz Oğlu
YÇYekta Çulpan
Yekta Çulpan
AHAylin Toplu Hocaoğlu
Aylin Toplu Hocaoğlu
FOFiliz Onat
Filiz Onat
This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID‐19 with a positive RT‐PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in‐hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID‐19. The median favipiravir trough concentration (C0‐trough) on Day 2 was 21.26 (interquartile range [IQR], 8.37–30.78) μg/mL, whereas it decreased significantly to 1.61 (IQR, 0.00–6.41) μg/mL on Day 4, the area under the concentration–time curve decreased by 68.5%. Day 2 C0‐trough of female patients was higher than male patients. Our findings indicate that favipiravir concentrations show significant variability during the treatment of COVID‐19 and therapeutic drug monitoring may be necessary to maintain targeted concentrations.

27 May 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
MGMedine I. Gulcebi
Medine I. Gulcebi
SGSeyhmus Gavas
Seyhmus Gavas
SSSanjay M. Sisodiya
Sanjay M. Sisodiya
Climate change—the global crisis with pervasive health impacts—has adverse consequences for people with epilepsy (PWE) who have low quality of life due to poor seizure control, socioeconomic disadvantages and comorbidities. This review focuses on the potential effects of climate change on the pharmacological characteristics of antiseizure medications (ASMs), antipsychotics and antidepressants. We note that findings particularly obtained from physicochemical stability studies have been demonstrated experimentally for some specific environmental conditions whereas studies for clinical outcome effects are very limited. Carbamazepine, valproate, phenytoin or lorazepam appear to be ASMs at risk of being affected by high temperature and/or humidity. Even the stability of blood samples needs to be considered during transportation to therapeutic drug monitoring units, particularly for the PWE living in low‐income countries that are facing the most challenges of climate change effects attributed to low infrastructure and healthcare system capacity. We need more urgent research investigating drug responses of PWE regarding especially the effects of adverse weather events such as heatwaves on physicochemical stability or pharmacokinetics of drugs in a complex interaction with the vulnerabilities of individuals, accompanying neuropsychiatric disorders and geographical challenges. Then we will be able to develop pharmacological treatment strategies to improve the quality of life of PWE during adverse weather events.

1 January 2017 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
ZGZafer Gören
Zafer Gören
MDMahluga J. Demirkapu
Mahluga J. Demirkapu
GAGökçe Akpinar Acet
Gökçe Akpinar Acet
SÇSanda Çali
Sanda Çali
MOMedine Gülçebi Idriz Oğlu
Medine Gülçebi Idriz Oğlu
Background/aim: Elderly patients are at high risk from drug-drug interactions (DDIs). This study evaluates the potential DDIs in Turkish elderly patients at a primary health care outpatient clinic. Materials and methods: Online database systems were used to examine DDIs on the prescriptions of patients (n = 1206). The clinical severity of DDIs was classified by the Lexi-Interact Online database. Results: Of the 5059 prescriptions, 33% were found to have DDIs. We detected 29 (0.9%) A, 380 (11.8%) B, 2494 (77.7%) C, 289 (9%) D, and 18 (0.6%) X risk rating category DDIs among the prescriptions. Prescriptions of female patients and patients aged between 65 and 72 years showed significantly higher number of DDIs. The frequency of DDIs increased both with the number of drugs and combined preparations per prescription. Acetylsalicylic acid and salbutamol were the most frequently prescribed drugs contributing to clinically important DDIs. Additionally, acetylsalicylic acid and escitalopram, which interact with each other, were found on the list of Beers criteria. The most predicted clinical outcomes of DDIs were increase in therapeutic efficacy and adverse/toxic reactions. Conclusions: Prediction of DDIs in elderly patients will provide better prescribing and drug safety. Use of nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, and beta-2 adrenergic receptor agonists should be closely monitored.